Based on the human and mouse genetic evidence supporting GIPR antagonism6, we previously developed anti-GIPR antagonistic antibodies as a potential therapeutic strategy for the treatment of obesity. This evidence concerns the gene GIPR and obesity due to melanocortin 4 receptor deficiency.